Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2026)

Inhibikase Therapeutics (IKT) has 5 years of Short-term Investments data on file, last reported at $120.8 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 511.97% year-over-year to $120.8 million in Q1 2026; TTM through Mar 2026 was $120.8 million, a 511.97% increase from a year earlier, with the FY2025 full-year figure at $39.5 million, down 3.68% from the prior year.
• Short-term Investments for Q1 2026 stood at $120.8 million, up from $39.5 million in the prior quarter.
• Over the last five years, Short-term Investments for IKT reached as high as $120.8 million in Q1 2026 and fell as low as $2.0 million in Q3 2023.
• Historically, Short-term Investments has averaged $24.5 million across 5 years, with a median of $19.0 million in 2023.
• Across the five-year window, Short-term Investments sank 90.51% in 2023 and soared 1575.91% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $15.9 million in 2022, then tumbled by 74.23% to $4.1 million in 2023, then surged by 904.51% to $41.1 million in 2024, then fell by 3.68% to $39.5 million in 2025, then surged by 205.47% to $120.8 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $120.8 million in Q1 2026, $39.5 million in Q4 2025, and $39.1 million in Q3 2025.